IgA nephropathy: a review of existing and emerging therapies

Sahibzadi Mahrukh Noor; Farah Abuazzam; Roy Mathew; Zhiwei Zhang; Amir Abdipour; Sayna Norouzi

doi:10.3389/fneph.2023.1175088

IgA nephropathy: a review of existing and emerging therapies

Front Nephrol. 2023 May 23:3:1175088. doi: 10.3389/fneph.2023.1175088. eCollection 2023.

Authors

Sahibzadi Mahrukh Noor¹, Farah Abuazzam¹, Roy Mathew¹, Zhiwei Zhang¹, Amir Abdipour¹, Sayna Norouzi¹

Affiliation

¹ Department of Nephrology, Loma Linda University, Loma Linda, CA, United States.

Abstract

IgA nephropathy (IgAN) is the most common form of primary glomerulonephritis worldwide. Recently, there have been multiple advances in the understanding of IgAN pathophysiology and therapeutic options. Despite the advent of new treatment options, individual risk stratification of the disease course and choosing the best treatment strategy for the patient remains challenging. A multitude of clinical trials is ongoing, opening multiple opportunities for enrollment. In this brief review we discuss the current approach to the management of IgAN and highlight the ongoing clinical trials.

Keywords: IgA nephropathy; SGLT2 inhibitors; budesonide; glucocorticoids; proteinuria; sparsentan.

Publication types

Review